RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
ImmunoMet Therapeutics, a US spinoff of Korea’s HanAll Biopharma, began a Phase I trial of its lead candidate in patients with solid tumor cancers. IM156 is an oxidative phosphorylation (OXPHOS) inhibitor. ImmunoMet, which uses cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, is headquartered at Houston’s JLABS, a biotech incubator established by Johnson & Johnson at the Texas Medical Center, where MD Anderson Cancer Center is also located.
Source: China Biotoday
